Does MIDAS reduction at 3  months predict the outcome of erenumab treatment? A real-world, open-label trial

ConclusionMIDASRes only partly reflects the 12-month outcome of erenumab treatment in CM, as it excludes more than one third of responders. A criterion based on the alternative consideration of  ≥ 50% reduction in MIDAS score or MMDs in the first three months of treatment represents a more precise and inclusive option.Trial registrationThe trial was retrospectively registered atwww.clinicaltrials.gov (NCT05442008).Graphical AbstractCGRP: Calcitonin Gene Related Peptide. MIDAS: MIgraine Disability Assessment. MMDs: monthly migraine days. MIDASRes: Patients with a MIDAS score reduction of at least 50% at T3. MMDRes: Patients with a MMDs reduction of at least 50% at T3. ResponderT13: Patients with a MMDs reduction from baseline of at least 50% in the last 4 weeks of observation period (after 13 erenumab administrations). T0: First erenumab administration. T3, T6, T9, T12: Follow-up visits at three, six, nine, and twelve months after first erenumab administration. T13: Last visit of the protocol.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research